Crown Bioscience to Showcase Progression in Human Surrogate Trials
Complete the form below to unlock access to ALL audio articles.
Crown Bioscience, Inc. will showcase their human surrogate trial platform at the 50th Annual ASCO Conference, taking place in Chicago, US, between 30th May and 3rd June. The HuTrialTM platform enables drug discovery and development companies to optimize their screening processes to ensure that only the most effective candidates are accelerated through to the clinic and onto improving patient care.
The most significant limitation to the development of new treatments in oncology is undoubtedly cost prohibition, as the attrition of a drug in the final stages of clinical trials carries significant financial implications for drug development. The HuTrial substitutes Phase-II trials at reduced cost, providing the opportunity for early decision making regarding drug candidate progression and significantly decreasing the risk of promoting ineffective therapeutics through the later stages of clinical testing.
The HuTrialTM platform substantially reduces the time and cost of phase-II trials and when used to identify patient biomarkers, it can effectively predict the clinical response of a prospective candidate before undergoing rigorous clinical testing. By evaluating all prospective treatments, surrogate trials can improve the success rate with which effective therapeutics reach the clinic and help reduce the chances of patients experiencing harmful or unpleasant side effects. HuTrials are conducted using Crown’s HuPrime® patient derived xenografts (PDX), where primary tumor cells are extracted directly from a patient and transplanted into surrogate, in most cases immunodeficient mice. As the cancer develops, prospective treatments can be administered to the surrogate host and the efficacy of prospective drug candidates can be observed and evaluated.
Jean-Pierre Wery, the President of Crown Bioscience comments; “At Crown Bioscience we are committed to improving the decision making process involved in submitting drug candidates for phase II and III clinical trials. As the most significant factor affecting the advancement of drug development is the cost of drug attrition in the later stages of clinical trials, it is important that we ensure that our clients do not waste resources on ineffective treatments. If we can assist them in identifying promising candidates early on, we can improve the rate at which effective new treatments are delivered into the clinic to improve patient outcomes. The HuTrialTM platform has the potential to help alleviate the socio-economic burden cancer has on the healthcare industry and assist in the global effort to convert cancer from a terminal condition to a chronic disease.”
The acclaimed ASCO Annual Meeting is attended by more than 25,000 oncology professionals, across a broad range of specialties. The itinerary includes workshops, education sessions, discussions, symposia and poster presentations to highlight clinical issues and frontline research and discovery. By bringing together individuals at the forefront of their respective fields, ASCO endeavors to unite the international oncological community with a view to sharing expertise, exploring new ideas, and further developing clinical and research techniques.
